Continuing Education Online Courses


Browse online courses available for Continuing Education Credit.

Click here to view more online courses and resources for clinicians.

2024 CE Courses
Collapse Community Considerations: The Ins and Outs of Immunotherapy for the Treatment of Cancer

Access Course

Do you know every organ system that immune-related adverse effects can affect?

Available beginning: January 4th, 2024

Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Original Course Date: January 04, 2024
On-Demand Release Date: Available Now

Approved Credit:
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Community Considerations: The Ins and Outs of Immunotherapy for the Treatment of Cancer
    Collapse LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team

    Access Course

    Are you familiar with how to incorporate lymphocyte-activation gene 3 (LAG-3) inhibition into the management of metastatic melanoma? Find out more here!

    Available beginning: November 16th, 2023

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 16, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team
    Collapse Certificate in Cancer Immunotherapy- SITC-G

    CP2_-_Copy.png

    The Society for Immunotherapy of Cancer (SITC) is pleased to offer physicians and qualified healthcare providers the opportunity to earn a Certificate in Cancer Immunotherapy, supporting their knowledge and skills to provide effective and safe care for patients treated with cancer immunotherapy. Learners can expect to develop a comprehensive understanding of cancer immunotherapies, including checkpoint inhibitors, cell therapies and many others, as well as the management of side effects, allowing them to successfully implement immunotherapy in clinical practice.  

    The Certificate in Cancer Immunotherapy consists of eight learning modules and a final assessment. You will earn SITC Graduate in Cancer Immunotherapy (SITC-G) certificate upon successfully completing all the 8 modules and qualfying in the final assessment. The SITC-G certificate identifies a healthcare provider as completing specialized training in cancer immunotherapy.  All modules are approved for CME, CNE, CPE and MOC credits, except where noted.

     

    Certificate- SITC Graduate in Cancer Immunotherapy / SITC-G

    CP1.png




     

     

     

    Cost of certification

    • SITC Member Price: $200
    • Non-Member Price: $250
    • SITC Member Price for Low to Lower-Middle Income Economies: $0*
    • SITC Non- member Price for Low to Lower-Middle Income Economies: $25*

    *Note: This is not available to those in the industry work setting.

     

    Click here for the List of Low to Lower-Middle Income Economies

     

     

    Target Audiences
    The primary target audience for the program is treating physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate will also be available to practicing, licensed NPs, PAs, and PharmDs (or RPh degree holders involved in direct clinical services), or global equivalent. The courses will be available to those who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Requirements
    The requirements to earn the certificate include:

    • Must be a treating physician (U.S. licensed MD / DO or global equivalent), or a practicing licensed NP, PA, PharmD or RPh degree holder involved in direct clinical services, or global equivalent
    • Complete the coursework (all eight modules)
      • anticipated to be approximately 1 hour each, for a total of 8 hours
    • Pass all end-of-module assessments
    • Successfully complete a comprehensive exam covering all modules

     

    Certificate Term
    The certificate term is two years. Then, to earn a current certificate, which allows one to continue to use the SITC-G designation, an individual will need to take and pass updated coursework and assessments. If one misses the deadline for reissuance, he or she will need to retake and pass the full program.

     

    Certificate Program Task Force
    Chair

    • Robert L. Ferris, MD, PhD – University of Pittsburgh Medical Center Hillman Cancer Center


    Members

    • Umar Farooq, MD – University of Iowa
    • Silvia Formenti, MD – Weill Cornell Medicine
    • Sigrun Hallmeyer, MD – Advocate Medical Group
    • Jose Lutzky, MD, FACP – University of Miami Sylvester Cancer Center
    • George Weiner, MD – University of Iowa

     

    Requirements
    The requirements to earn the certificate include:
    • Complete the coursework (all eight modules)—anticipated to be approximately 1.5 hours each for a total of 12–16 hours
    • Successfully complete a comprehensive exam covering all modules

     

    Learner Notification

    This program consists of eight modules. Continuing Education credit information for the modules can be found below, and at the module level. Please note, that each module counts for a maximum of 1.50 AMA PRA Category 1 Credits™ for physicians and 1.50 contact hours for nurses and 1.50 knowledge-based contact hours for pharmacists. 

     

    Continuing Education (CE) Language
    Certificate in Cancer Immunotherapy Webseries Online

    Physicians / Nurses / Pharmacists

    download.png

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC, PACE, and SITC. Amedco LLC and PACE are jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Credit Designation Statement – Upon successful completion of all content in this program, Amedco LLC and PACE designate this enduring material for a maximum of 8.25 AMA PRA Category 1 CreditsTM for physicians and 8.25 contact hours for nurses and 8.25 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

     

    Medical Physicist (CAMPEP) Credit Designation
    This program has been approved by the Commission on Accreditation of Medical Physics Education Programs (CAMPEP) for a total of 8.25 MPCEC hours.


    ABIM MOC Credit
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.25 Part 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

    Original Course Date: December 06, 2022
    On-Demand Release Date: Available Now
    MORE INFOMORE INFO Certificate in Cancer Immunotherapy- SITC-G
    Collapse Certificate in Cancer Immunotherapy Module 8: Implementing Cancer Immunotherapy in Clinical Practice

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 8: Implementing Cancer Immunotherapy in Clinical Practice, will cover the practical aspects of instituting immunotherapy treatments in a clinical practice, such as education considerations, value-based care, and access to patient and provider resources.

     

    • Original Release Date: May 2, 2022
    • Expiration Date: May 2, 2026
    • Date of Last Review: April 2024
    • Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC)
    • Estimated time to complete the activity: 60 minutes
    • For additional information about the accreditation of this activity, please visit https://partnersed.com
    • Computer system hardware/software requirements: SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

     

    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

     

    Educational Objectives

    Topic Upon completion of this activity, participants should be able to:

    How Cancer Immunotherapy Integrates
    into Value-based Clinical Care

    • Contrast the role of IO versus standard cancer therapies in the setting of personalized care approaches.
    • Evaluate IO in the NCCN/ASCO value framework.
    • Interpret published data on Patient Reported Outcomes.
    • Analyze cost of IO in the setting of quality of life, earning potential preserved, duration of response, and duration of therapy.

    Optimizing Resources for Cancer Immunotherapy Patient Care

    • Identify and access local, regional and national support foundations and financial support programs.
    • Identify patient education resources.
    • Tailor patient and staff communication to the dynamic and complex nature of IO, including continuous education strategies, telemedicine, etc.

    Educating Non-cancer Professionals
    about Cancer Immunotherapy

    • Build a dedicated multidisciplinary team with expertise in immuno-oncology administration, adverse events diagnosis and management.
    • Develop subspecialty-targeted learning programs for education on IO.
    • Identify best practices of communicating with primary care physicians and emergency physician on how to recognize treatment related adverse events.

    Patient Selection in Immunotherapy

    • Interpret the value and limitations of current biomarkers in different IO settings.
    • Distinguish the risk/benefit ratios for each individual case based on published data, expert opinion or personal experience.
    • Describe the key elements of a detailed informed consent discussion.
    • Describe IO therapy in populations traditionally deemed ineligible for clinical trials 

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.



    Faculty and Disclosure of Conflict of Interest

    PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

     

    All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

     

    Presenting Faculty

    Conflicts of Interest

    Sigrun Hallmeyer, MD

    Director, Advocate Medical Group

    Member, Division of Hematology/Oncology

    Advocate Lutheran General Hospital, Park Ridge, IL

    Consultant: Cardinal Health

    Certificate Program Task Force

    Conflicts of Interest

    Robert L. Ferris, MD, PhD (Chair)

    UPMC Hillman Cancer Center

    Researcher: Astra-Zeneca/Medimmune, Bristol Myers Squibb, Merck, Novasenta, Tesaro

    Consultant/Advisor/Speaker: Achilles Therapeutics; Adagene Incorporated, Adaptimmune, Aduro Biotech Inc, Astra-Zeneca/MedImmune; Bicara Therapeutics, Inc, Bristol-Myers Squibb, Brooklyn Immunotherapeutic, Cantenion, Coherus BioSciences, Inc, CureVac, Cytoagents, Eisai Europe Limited,

    EMD Serono, Everest Clinical Research Corporation, F. Hoffman-La Roche Ltd., Federation Bio, Inc, Genmab,

    Genocea Biosciences, Inc, Hookipa Biotech GmbH, Instill Bio, Inc, Kowa Research Institute, Inc, Lifescience Dynamics Limited, MacroGenics, Inc, MeiraGTx, LLC, Merck, Merus N.V,

    Mirati Therapeutics, Inc, Mirror Biologics Inc, Nanobiotix,

    Novartis Pharmaceutical Corporation, Novasenta,

    Numab Therapeutics AG, OncoCyte Corporation, Pfizer,

    PPD Development, L.P., Rakuten Medical, Inc, Regeneron,

    Sanofi, Seagen, Inc, SIRPant Immunotherapeutics, Inc, Tesaro, Vir Biotechnology, Inc, Zymeworks Inc

    Stocker holder: Novasenta

    Umar Farooq, MD

    University of Iowa

    Researcher: Regeneron Pharmaceuticals; Consultant/Advisor/Speaker: Immpact Bio, Caribou Biosciences, Kite Pharma, MoprhoSys;

    Silvia Formenti, MD

    Weill Cornell Medicine

    Grant/Research Support: Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex, ViewRay, AstraZeneca

    Consultant/Honoraria: Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Genentech/ROCHE, Nanobiotix

    Sigrun Hallmeyer, MD

    Advocate Medical Group

    Consultant: Cardinal Health

    Jose Lutzky, MD, FACP

    University of Miami Sylvester Cancer Center

    Researcher: BMS

    Consultant/Advisor/Speaker: Castle, Iovance, Vyriad, Replimune, Takeda, Oncotelic, T-Nanobio, Agenus, Celldex

    Independent Contractor: BMS, Novartis, Iovance, Replimune, Regeneron, InstilBio, Syntrix, BioNtech, Foghorn, Trisalus, Agenus, Inmatics, Takeda, Dragonfly

     

    George Weiner, MD

    University of Iowa

    Researcher: Regeneron, Pfizer



    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physicians Continuing Education

    PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    To receive CME credit and/or MOC points, you MUST pass the posttest and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PACE’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. By sharing your Diplomate Board ID # and DOB, you are giving PACE permission to use this information/data to report your participation to these Boards JA-PARS.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 1.0 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-24-098-H01-P)

    Type of Activity: Knowledge

     

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Medical Physicist (CAMPEP)

    This program has been approved by The Commission on Accreditation of Medical Physics Education Programs (CAMPEP) for 0.75 MPCEC Hours.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Method of Participation and Request for Credit

    During the period 5/2/2022 through 5/2/2026 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 75% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Original Course Date: March 01, 2021
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • CAMPEP: 0.75 hours Medical Physics Continuing Education Credit

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 8: Implementing Cancer Immunotherapy in Clinical Practice
    Collapse Certificate in Cancer Immunotherapy Module 7: CAR T Cell and Cellular Therapy

    Check out the updated version with new FDA drug approvals (As of 04/05/2023*), Available now......

    • Certificate in Cancer Immunotherapy Module 7: CAR T Cell and Cellular Therapy
    • Original Release Date: December 1, 2021
    • Expiration Date: April 1, 2026
    • Date of Last Review: March 2024
    • Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC)
    • Estimated time to complete the activity: 30 minutes
    • For additional information about the accreditation of this activity, please visit https://partnersed.com
    • Computer system hardware/software requirements: SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 7: CAR T Cell and Cellular Therapy, will cover the mechanisms and clinical administration of cellular therapies for cancer, including an emphasis on adverse event management.


    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Educational Objectives
    Upon completion of this activity, participants should be able to:

     

    Basic Mechanisms of Adoptive T Cell Immunotherapy

    • Describe the biologic basis for adoptive T cell therapy of cancer.
    • Define significance of different target antigens and signaling moieties in CAR T cell activity.
    • Contrast the differences between CAR T and other adoptive T cell strategies.
    • Distinguish between different CAR T preparations such as target antigen but also viral vector culture conditions and signaling moieties.

    Cellular therapies and Current Clinical Indications

    • Classify the types of adoptive T cell therapies approved for cancer treatment.
    • Describe clinical indications of approved therapies.
    • Describe off-label uses of CAR T cell therapy.

    Patient Selection for
    T Cell-based Therapy

    • Identify when patients should be referred for cellular therapy.
    • Recognize contraindications to adoptive cell administration.
    • Describe the timeline of adoptive cellular therapy preparation and administration.

    Management of CAR T Cell
    Administration and Adverse Events

     Describe the preparation of CAR T and patient disease management prior to administration.

    • Recognize the different types and patterns of CAR T-related toxicity.
    • Outline approaches to monitoring patients for CAR T-related toxicity including cytokine release syndrome and neurotoxicity.
    • Describe grading and management of cytokine release syndrome and neurotoxicity.
    • Describe typical kinetics of response of malignancy to CAR T cell therapy.
    • Describe long term monitoring and management of CAR T cell patients including identification and management of long term toxicities such as cytopenias and immuno-deficiency.
    • Describe the resources required for outpatient management of CAR T cell therapy

    Requirements for CAR T Cell Program Development

    • Describe the requirements for site certification for administering cellular therapies, including REMS training.
    • Identify other medical specialists who need to participate in REMS training and care of CAR T patients.
    • Outline data reporting requirements for CAR T cell programs.
    • Describe in-patient versus out-patient management and monitoring of CAR T cell patients.

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


    Faculty and Disclosure of Conflict of Interest

    PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

     

    All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

     

    Presenting Faculty

    Conflicts of Interest

    Carl June, MD

    Richard W. Vague Professor In Immunotherapy, Department of Pathology and Laboratory Medicine

    Director, Parker Institute for Cancer Immunotherapy

    Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    Novartis: Royalties; AC Immune, Bluesphere Bio, Cellares, Celldex, Cabaletta, Carisma, DeCART, Kiadis, Poseida, Viracta, WIRB-Copernicus Group: Consulting

    Certificate Program Task Force

    Conflicts of Interest

    Robert L. Ferris, MD, PhD (Chair)

    UPMC Hillman Cancer Center

    Researcher: Astra-Zeneca/Medimmune, Bristol Myers Squibb, Merck, Novasenta, Tesaro

    Consultant/Advisor/Speaker: Achilles Therapeutics; Adagene Incorporated, Adaptimmune, Aduro Biotech Inc, Astra-Zeneca/MedImmune; Bicara Therapeutics, Inc, Bristol-Myers Squibb, Brooklyn Immunotherapeutic, Cantenion, Coherus BioSciences, Inc, CureVac, Cytoagents, Eisai Europe Limited,

    EMD Serono, Everest Clinical Research Corporation, F. Hoffman-La Roche Ltd., Federation Bio, Inc, Genmab,

    Genocea Biosciences, Inc, Hookipa Biotech GmbH, Instill Bio, Inc, Kowa Research Institute, Inc, Lifescience Dynamics Limited, MacroGenics, Inc, MeiraGTx, LLC, Merck, Merus N.V,

    Mirati Therapeutics, Inc, Mirror Biologics Inc, Nanobiotix,

    Novartis Pharmaceutical Corporation, Novasenta,

    Numab Therapeutics AG, OncoCyte Corporation, Pfizer,

    PPD Development, L.P., Rakuten Medical, Inc, Regeneron,

    Sanofi, Seagen, Inc, SIRPant Immunotherapeutics, Inc, Tesaro, Vir Biotechnology, Inc, Zymeworks Inc

    Stocker holder: Novasenta

    Umar Farooq, MD

    University of Iowa

    Researcher: Regeneron Pharmaceuticals; Consultant/Advisor/Speaker: Immpact Bio, Caribou Biosciences, Kite Pharma, MoprhoSys;

    Silvia Formenti, MD

    Weill Cornell Medicine

    Grant/Research Support: Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex, ViewRay, AstraZeneca

    Consultant/Honoraria: Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Genentech/ROCHE, Nanobiotix

    Sigrun Hallmeyer, MD

    Advocate Medical Group

    Consultant: Cardinal Health

    Jose Lutzky, MD, FACP

    University of Miami Sylvester Cancer Center

    Researcher: BMS

    Consultant/Advisor/Speaker: Castle, Iovance, Vyriad, Replimune, Takeda, Oncotelic, T-Nanobio, Agenus, Celldex

    Independent Contractor: BMS, Novartis, Iovance, Replimune, Regeneron, InstilBio, Syntrix, BioNtech, Foghorn, Trisalus, Agenus, Inmatics, Takeda, Dragonfly

     

    George Weiner, MD

    University of Iowa

    Researcher: Regeneron, Pfizer


    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    To receive CME credit and/or MOC points, you MUST pass the posttest and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PACE’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. By sharing your Diplomate Board ID # and DOB, you are giving PACE permission to use this information/data to report your participation to these Boards JA-PARS.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
    (Universal Activity Number - JA4008073-9999-24-081-H01-P)
    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Medical Physicists (CAMPEP) Credit Designation Statement

    This program has been approved by the Commission on Accreditation of Medical Physics Education Programs, Inc. for a total of 0.50 MPCEC credit hours. 2162193.

     

    Instructions for Credit
    During the period 12/1/2021 through 4/1/2026 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: February 01, 2021
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 0.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.50 hours Contact Hour
  • ANCC: 0.50 hours Contact Hour
  • CAMPEP: 0.05 hours Medical Physics Continuing Education Credit

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 7: CAR T Cell and Cellular Therapy
    Collapse Certificate in Cancer Immunotherapy Module 6: Oncolytic Viruses and Intralesional Therapy

    Published 10/11/2021

    Check out our updated version- Certificate in Cancer Immunotherapy - Module 6 (As of 11/29/2022*), Available now....

    Please note, this activity does not offer continuing education credit.

     

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 6: Oncolytic Viruses and Local Therapy, will cover the biological foundation and clinical implementation of intratumoral therapies and oncolytic viruses.


    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty

    Brian Gastman, MD
    Professor, Department of Surgery, School of Medicine
    Member, Hematopoietic and Immune Cancer Biology Program, Case Comprehensive Cancer Center
    Case Western Reserve University, Cleveland, OH
    Department of Plastic Surgery
    Cleveland Clinic Main Campus, Cleveland, OH

    Ann Silk, MD, MS
    Co-Director of the Merkel Cell Carcinoma Center of Excellence
    Dana-Farber Cancer Institute, Boston, MA
     

    Learning Objectives

    Topic At the conclusion of this activity, the participant should be able to:

    Basic Mechanisms of Oncolytic Viruses
    and Intralesional Therapy

    • Describe the rationale for intralesional therapy as a strategy for modulating tumor cells and promoting immunity.
    • Distinguish the differences between oncolytic viruses and non-viral intralesional approaches.  
    • Classify the different viruses available for cancer immunotherapy and their advantages and disadvantages.
    • List approved oncolytic viruses and intralesional agents.
    • Describe the dual mechanism of action of oncolytic viruses in mediating anti-tumor immunity.
    • Identify how oncolytic viruses can deliver transgenes to promote anti-tumor activity.
    • Describe alternative delivery routes of administration for oncolytic viruses and other intralesional agents.

    Patient Selection and Monitoring
    for Oncolytic Virus Therapies and Intralesional Therapy

    • Identify eligible patients for oncolytic viruses and intralesional therapy.
    • Determine when oncolytic viruses and/or intralesional therapy should be considered in patient management.
    • Select appropriate tumors for injection of an oncolytic virus and/or intralesional therapy.
    • Determine the volume of oncolytic virus and/or intralesional agent for patient therapy.
    • Describe the process of injecting oncolytic viruses and/or intralesional treatments in patients with cancer.
    • Identify the role of interventional radiology in administration of intralesional treatments to deep and/or visceral tumors.
    • Apply appropriate injection site management following injection of intralesional agents.
    • Define the patterns of response with oncolytic viruses and other intralesional treatments.
    • Identify contraindications to oncolytic virus and/or intralesional therapy.
    • Outline the potential role for oncolytic viruses and intralesional therapy as part of combination regimens for patients with cancer.

    Management of Oncolytic Virus and intralesional therapy Adverse Events

    • Identify the most common adverse events seen with oncolytic viruses and/or other intralesional treatments.
    • Prescribe appropriate intervention for managing common adverse events associated with oncolytic viruses and intralesional therapies.

    Logistical and Biosafety Issues
    Associated with Oncolytic Virus Therapy

    • Describe the biosafety issues associated with oncolytic virus administration.
    • Recognize the potential for bioshedding and contact transmission associated with oncolytic viruses.
    • Explain how to modify patient flow to optimize integration of oncolytic viruses and intralesional treatments into clinical practice.
    • Implement standard operating procedures for safe delivery of oncolytic viruses and intralesional treatments into clinical practice.


     

     


     

    SITC Online Education Disclaimer

     

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     


    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. To earn the SITC-G designation, you must participate in the entire activity.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: January 04, 2021
    On-Demand Release Date: Available Now

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 6: Oncolytic Viruses and Intralesional Therapy
    Collapse Certificate in Cancer Immunotherapy Module 5: Other Approaches (Cytokines, Vaccines, and Immune Cell Engagers)

    Published July 7, 2021

     

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 5: Other Approaches (Cytokines, Vaccines, and Immune Cell Engagers), will cover the biological foundation and clinical implementation of cytokines, vaccines and immune cell engagers as immunotherapies for cancer, including adverse event management.


    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty

    Umar Farooq

    Senior Vice President 

    Global Head of Cell Therapy Research

    Universty of Iowa

     

    Learning Objectives

    Topic At the conclusion of this activity, the participant should be able to:

    Basic Mechanisms

    • Define the types and functions of cytokines and chemokines used in cancer immunotherapy.
    • Distinguish among the various types of cancer vaccines.
    • Describe the different types and functions of tumor antigens used in cancer vaccines.
    • Classify the different delivery platforms for cancer vaccines.
    • Describe how personalized cancer vaccines differ from standard cancer vaccines.
    • Identify different methods and routes of administration of immunotherapy agents.
    • Define the types of immunologic adjuvants and their distinct functions in promoting immune responses.
    • Recognize the role of innate immune activators in promoting tumor immunotherapy.
    • Describe the mechanism of action of immune cell engagers.
    • Compare and contrast immune cell engagers with adoptive cellular therapies.
    • Describe potential mechanisms of relapse following immune cell engager therapies.

    Clinical Use and Development

    • Appreciate the historical data on vaccine and cytokine treatment of malignancy.
    • List current clinical indications for vaccines, cytokines, and immune cell engagers in cancer treatment.
    • Explain how immunologic boosting can enhance anti-tumor immunity with vaccines.
    • Describe the role of immunotherapy and vaccines in cancer prevention.
    • Characterize new and emerging vaccines, cytokines and immune cell engagers under clinical investigation.
    • Describe how cytokine levels may be used as prognostic and predictive biomarkers for cancer immunotherapy.

    Combination Approaches

    • Describe how cytokines, vaccines, and immune cell engagers can be combined with other immunotherapy agents to promote T cell recruitment and anti-tumor immunity.
    • Recognize the role of non-immune agents in promoting tumor immunity in combination with cytokines, vaccines, and immune cell engagers.
    • Define immunogenic cell death (ICD) and describe how combination approaches promote ICD and anti-tumor immunity.
    • Explain the abscopal effect of local therapy.
    • Describe how other agents can enhance immunotherapy.

    Patient Selection, Management and Monitoring

    • Apply criteria for patient selection for IL-2 or interferon therapy.
    • Identify contraindications to treatment with cytokines.
    • Describe methods needed to safely monitor patients on high-dose IL-2 therapy.
    • Describe criteria for patient selection for vaccine treatment.
    • Identify contraindications to treatment with vaccine therapy.
    • Describe patient selection criteria for immune cell engager therapies.
    • Identify contraindications to immune cell engager therapies.
    • Determine duration of treatment and when to assess patients for clinical response.

    Management of Adverse Events

    • Recognize the type and severity of adverse events associated with cytokine, vaccine, and immune cell engager administration.
    • Apply appropriate interventions to ameliorate toxicities associated with cytokines, vaccines, and immune cell engagers.  
    • Identify appropriate institutional and provider resources and procedures needed to manage cytokine-related toxicities.
    • Recognize the importance of continuing education for high-dose cytokine delivery teams.
    • Recognize the interactions between cytokines, vaccines, and immune cell engagers with other immunotherapy and non-immunotherapy cancer agents for causing unknown or unexpected adverse events.

     


     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     


    Certificate in Cancer Immunotherapy Webseries, Module Five

    Date of CE Release:  July 5, 2021

    Date of CE Expiration: July 5, 2024

    Approximate Time to Complete: 90 minutes

     

    Acknowledgement of Financial Commercial Support

    No financial commercial support was received for this educational activity.

     

    Acknowledgement of In-Kind Commercial Support

    No in-kind commercial support was received for this educational activity.

     

    Satisfactory Completion 

    Learners must listen to each self-directed audio recording while following along with the visual slides/pass the posttest with a score of 80% or higher and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. 

    If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Society for Immunotherapy of Cancer.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Amedco Joint Accreditation #4008163.

     

    Physicians (ACCME) Credit Designation
    Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

     

    Nurses (ANCC) Credit Designation
    Amedco LLC designates this activity for a maximum of 1.50 ANCC contact hours.

     

    Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
    Amedco LLC designates this activity for a maximum of 1.50 knowledge-based CPE contact hours.

    UAN(s): UAN: JA4008163-9999-21-141-H04-P / JA4008163-9999-21-141-H04-T

     

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

     

    Medical Physicist (CAMPEP)
    This program has been approved by The Commission on Accreditation of Medical Physics Education Programs (CAMPEP) for 1.50 MPCEC Hours.

     

    American Board of Internal Medicine (ABIM) MOC Credit
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.

     

    Disclosure of Conflict of Interest

    The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1—6.2, 6.5)

    All individuals in a position to control the content of CE are listed below.

    First Name

    Last Name

    Relationship: Commercial Entity

    Aaron

    Brodersen

    NA

    Leisha

    Emens

    Consultant: Genentech, F Hoffman La Roche, Syndax, Lilly, AbbVie, Amgen, Astrazeneca, Bayer, Bristol Myers Squibb, Celgene, Chugai, Genentech, F Hoffman La Roche, Gritstone, Medimmune, Macrogenics, Novartis, Peregrine, Replimune, Silverback, Vaccinex; Contracted Research: Aduro Biotech, Astrazeneca, Bristol Myers Squibb, Corvus, EMD Serono, Genentech, F Hoffman La Roche, Maxcyte, Merck, Tempest; Royalties: Elsevier

    Umar

    Farooq

    Consultant: Kite Pharma, Inc

    James

    Gulley

    NA

    Tiffany

    Klopp

    NA

    Jane

    Kosirog-Glowcki

    NA

    Claire

    Leischer

    NA

    Francesco

    Marincola

    Consulting: Calidi Biotechnologie

    Scott

    McGee-Plys

    NA

    Edwin

    O'Sullivan

    Ownership Interest: Aveo Oncology

    Emily

    Shepard

    NA

    Jo

    Shultz

    NA

    Lianne Wiggins

    NA

     

    Method of Participation and Request for Credit
    During the period 7/1/2021 through 7/1/2024 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: December 07, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1.50 hours Contact Hour
  • ANCC: 1.50 hours Contact Hour
  • CAMPEP: 1.50 hours Medical Physics Continuing Education Credit

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 5: Other Approaches (Cytokines, Vaccines, and Immune Cell Engagers)
    Collapse Certificate in Cancer Immunotherapy Module 3: Immune Checkpoint Blockade

    Published December 1, 2020

    Check out the updated version with new FDA drug approvals (As of 03/20/2023*), Available now......

     

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 3: Immune Checkpoint Blockade, will cover the biological foundation of immune checkpoint blockade therapies as well as diving into their clinical use.


    Click on image for FREE PREVIEW


     

     

     

     

     

     

     

     

     

     

    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty
    Robert L. Ferris, MD, PhD
    Hillman Professor of Oncology
    Director, UPMC Hillman Cancer Center
    Associate Vice Chancellor for Cancer Research
    University of Pittsburgh Medical Center, Pittsburgh, PA

     

    Learning Objectives

    Topic

    At the conclusion of this activity, the participant should be able to:

    Basic Mechanisms of Checkpoint
    Blockade in Immunotherapy
    • Describe the basis for co-stimulation in T cell activation and priming.
    • Explain the mechanisms and consequences of co-inhibitory immune checkpoint receptors (ICR).
    • Identify negative downstream regulatory motifs and pathways associated with ICR signaling.
    • Distinguish the distinct activities of antibodies that target PD-1 compared to those that target PD-L1
    Biomarkers of Response to ICB and General Clinical Utility
    • Describe major biomarkers for patient eligibility for the use of immune checkpoint blockade across cancers (PD-L1 expression and extent, IFN signature, CD8 infiltration, Tumor Mutational Burden) and their relative value for prediction of clinical benefit.
    • Distinguish between validated and investigational biomarkers.
    • Describe the use of biomarkers to predict ORR, PFS and OS.
    • Identify patient-specific factors that may predict response (tumor burden, prior chemotherapy exposure, age, gender, site of disease, prior radiotherapy, etc.).
    Immune Checkpoint Inhibitors and Combination Approaches
    • Describe general clinical benefits of ICB with PD-1 or CTLA-4 monotherapy, or ICB combinations (including IO+IO and IO+other cancer therapy combinations).
    • Distinguish the benefits, dose and schedules of combination ICB versus the benefits, dose and schedule of conventional therapies (chemotherapy, radiation therapy and targeted therapies).
    • Identify validated vs investigational ICB combinations, and relevant cancer types.
    Monitoring Response to Checkpoint Blockade
    • Distinguish response criteria in ICB vs standard cancer treatment.
    • Describe kinetics and patterns of response to ICB.
    • Distinguish pseudoprogression from true disease progression.
    • Identify when to suspend or discontinue ICB treatment.


     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.



    Continuing Education Information

    Date of CE Expiration: Jan. 8, 2026
    Approximate Time to Complete:  90 minutes

    Acknowledgement of Financial Commercial Support
    No financial commercial support was received for this educational activity.

    Acknowledgement of In-Kind Commercial Support
    No in-kind commercial support was received for this educational activity.

    Satisfactory Completion

    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physicians (ACCME) Credit Designation

    PACE designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

     

    Nurses (ANCC) Credit Designation

    PACE designates this activity for a maximum of 1.50 ANCC contact hours.

     

    Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

    PACE designates this activity for a maximum of 1.50 knowledge-based CPE contact hours.

    (Universal Activity Number - JA4008073-9999-24-014-H01-P)

    Type of Activity: Knowledge

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

     

    Medical Physicists (CAMPEP) Credit Designation Statement

    This program has been approved by the Commission on Accreditation of Medical Physics Education Programs, Inc. for a total of 1.50 MPCEC credit hours. 2162189.


    American Board of Internal Medicine (ABIM) MOC Credit

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    To receive CME credit and/or MOC points, you MUST pass the posttest and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PACE’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. By sharing your Diplomate Board ID # and DOB, you are giving PACE permission to use this information/data to report your participation to these Boards JA-PARS.

    Disclosure of Conflict of Interest

    PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

     

    FIRST NAME

    LAST NAME

    RELATIONSHIP:COMMERCIAL INTEREST

    Robert

    Ferris

    Researcher: Astra-Zeneca/Medimmune, Bristol Myers Squibb, Merck, Novasenta, Tesaro

    Consultant/Advisor/Speaker: Achilles Therapeutics; Adagene Incorporated, Adaptimmune, Aduro Biotech Inc, Astra-Zeneca/MedImmune; Bicara Therapeutics, Inc, Bristol-Myers Squibb, Brooklyn Immunotherapeutic, Cantenion, Coherus BioSciences, Inc, CureVac, Cytoagents, Eisai Europe Limited,

    EMD Serono, Everest Clinical Research Corporation, F. Hoffman-La Roche Ltd., Federation Bio, Inc, Genmab,

    Genocea Biosciences, Inc, Hookipa Biotech GmbH, Instill Bio, Inc, Kowa Research Institute, Inc, Lifescience Dynamics Limited, MacroGenics, Inc, MeiraGTx, LLC, Merck, Merus N.V,

    Mirati Therapeutics, Inc, Mirror Biologics Inc, Nanobiotix,

    Novartis Pharmaceutical Corporation, Novasenta,

    Numab Therapeutics AG, OncoCyte Corporation, Pfizer,

    PPD Development, L.P., Rakuten Medical, Inc, Regeneron,

    Sanofi, Seagen, Inc, SIRPant Immunotherapeutics, Inc, Tesaro, Vir Biotechnology, Inc, Zymeworks Inc

    Stocker holder: Novasenta

     

    Jose

    Lutzky

    Researcher: BMS

    Consultant/Advisor/Speaker: Castle, Iovance, Vyriad, Replimune, Takeda, Oncotelic, T-Nanobio, Agenus, Celldex

    Independent Contractor: BMS, Novartis, Iovance, Replimune, Regeneron, InstilBio, Syntrix, BioNtech, Foghorn, Trisalus, Agenus, Inmatics, Takeda, Dragonfly

        Certificate Program Task Force
    Robert Ferris See above.
    Umar  Farooq Researcher: Regeneron Pharmaceuticals; Consultant/Advisor/Speaker: Immpact Bio, Caribou Biosciences, Kite Pharma, MoprhoSys
    Silvia Formenti

    Grant/Research Support: Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex, ViewRay, AstraZeneca

    Consultant/Honoraria: Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Genentech/ROCHE, Nanobiotix

    Sigrun Hallmeyer Consultant: Cardinal Health
    Jose  Lutzky See above. 

     

    Method of Participation and Request for Credit
    Up until Jan. 8, 2026, participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Media
    Internet
     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.
     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: December 01, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1.50 hours Contact Hour
  • ANCC: 1.50 hours Contact Hour
  • CAMPEP: 1.50 hours Medical Physics Continuing Education Credit

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 3: Immune Checkpoint Blockade
    Collapse Certificate in Cancer Immunotherapy Module 4: Managing Immune Checkpoint Inhibitor Adverse Events

    Published September 15, 2021

     

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 4: Managing Immune Checkpoint Inhibitor Adverse Events, will cover the presentations, diagnosis and management of adverse events resulting from immune checkpoint inhibitor treatments.


    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty
    Jason Luke, MD, FACP
    Associate Professor of Medicine, Division of Hematology/Oncology
    Director, Cancer Immunotherapeutics Center within the UPMC Hillman Cancer Immunology and Immunotherapy Program
    University of Pittsburch Medical Center, Pittsburgh, PA
     

    Enduring Material Learning Notification

    SITC
    Certificate in Cancer Immunotherapy Module 4: Managing Immune Checkpoint Inhibitor Adverse Events

    Date of CE Release:  September 15, 2021
    Date of CE Expiration: September 15, 2024
    Online

     

    Acknowledgement of Financial Commercial Support
    No financial commercial support was received for this educational activity.

     

    Acknowledgement of In-Kind Commercial Support
    No in-kind commercial support was received for this educational activity.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/complete a posttest for MOC credit and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety.  Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.   

     

    Joint Accreditation Statement

    A picture containing drawingDescription automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Society for Immunotherapy of Cancer.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
    Amedco Joint Accreditation #4008163.

     

    Physicians (ACCME) Credit Designation

    Amedco LLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

     

    Nurses (ANCC) Credit Designation

    Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

     

    Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

    Amedco LLC designates this activity for a maximum of 1.00 knowledge-based CPE contact hours.

     

    UAN(s): JA4008163-9999-21-175-H04-P / JA4008163-9999-21-175-H04-T

     

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

     

    Medical Physicist (CAMPEP)

    This program has been approved by The Commission on Accreditation of Medical Physics Education Programs (CAMPEP) for 1.00 MPCEC Hours.
     

    American Board of Internal Medicine (ABIM) MOC Credit

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


    You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.

     

    Learning Objectives

    Topic After attending this program, you should be able to
    Recognition, Frequency and Kinetics of Immune-Related Toxicities
    • Identify the immune-related toxicities associated with checkpoint inhibition.
    • Classify severity of immune related side effects.
    • Describe the kinetics of immune-related toxicities of immune checkpoint inhibition.
    • Distinguish immune-related side effects from those related to disease progression.
    • Recognize and manage hyperprogression.
    • Manage concurrent multiple adverse events.
    • Manage immunosuppressive medications used to treat adverse events.
    Management of Immune-Related
    Colitis
    • Describe how to diagnose immune-related colitis.
    • Describe the frequency and time to development of immune-related colitis associated with distinct immunotherapeutic drugs.
    • Manage grade 1/2 colitis and steroid refractory immune-related colitis.
    Management of Immune-Related Pneumonitis
    • Diagnose immune-related pneumonitis.
    • Describe the frequency of immune-related pneumonitis with distinct cancer types.
    • Manage immune-related pneumonitis.
    Management of Immune-Related Endocrinopathies
    • List immune-related endocrinopathies.
    • Recognize and diagnose immune-related endocrinopathies.
    • Treat immune-related endocrinopathies based on the severity of the toxicity.
    • Counsel patients about long term consequences and management of endocrinopathies.
    Management of Immune-Related
    Hepatitis
    • Recognize and diagnose immune-related hepatitis.
    • Treat immune-related hepatitis based on the severity of the toxicity.
    Management of Immune-Related
    Cutaneous Events
    • List immune-related cutaneous events.
    • Recognize and diagnose immune-related cutaneous events.
    • Treat immune-related cutaneous events based on the severity of the toxicity.
    Management of Other (Rare)
    Immune-related Adverse Events
    • List rare immune-related adverse events.
    • Recognize and diagnose rare immune-related adverse events.
    • Treat rare immune-related adverse events based on the severity of the toxicity.
    Unique aspects of IO-containing combination therapies
    • Describe the patterns and severity of adverse events with IO-containing combination therapies relative to the single agents.
    • Distinguish between immune-related and other toxicities in patients receiving IO-containing combination therapies.
    Chronic Toxicities Associated with
    Cancer Immunotherapy
    • List chronic toxicities of immunotherapy.
    • Describe the time course of chronic toxicities of immunotherapy.
    • Manage the chronic toxicities of immunotherapy.
    Management of Non-Immune-Mediated Adverse Events
    • List non-immune-mediated adverse events.
    • Recognize non-immune-mediated adverse events.
    • Treat non-immune-mediated adverse events.
    Management of ICB therapy in
    the Context of an Adverse Event
    • Describe when ICB therapy can be continued, reduced or discontinued in the face of toxicity.
    • Describe when ICB therapy can be reinstated following management of toxicity.

     

     


     

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     



    Disclosure of Conflict of Interest
    The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­6.2, 6.5)

    All individuals in a position to control the content of CE are listed below.

    First Name

    Last Name

    Relationship: Commercial Entity

    Michael

    Dougan

    Consultant: Genentech-Roche, Tillotts Pharma, Partner Therapeutics

    Tiffany

    Klopp

    NA

    Lisa

    Kottschade

    Consultant: BMS

    Claire

    Leischer

    NA

    Jason

    Luke

    Consulting: Fstar, RefleXion, Xilio Abbvie, Alnylam, Bayer, Bristol-Myers Squibb, Checkmate, Crown, Cstone, Eisai, EMD Serono, Flame, Genentech, Gilead, Kadmon, KSQ, Janssen, Immunocore, Inzen, Macrogenics, Merck, Mersana, Nektar, Novartis, Pfizer, Regeneron, Ribon, Rubius, Silicon, Synlogic, TRex, Werewolf, Xencor; Contracted Research: AbbVie, Agios (IIT), Array (IIT), Astellas, Bristol-Myers Squibb (IIT & industry), Corvus, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Numab, Replimmune, Rubius, Spring bank, Synlogic, Takeda, Trishula, Tizona, Xencor

    Jose

    Lutzky

    Consultant: Castle, Kimera Labs,Regeneron, Replimune, Iovance; Contracted Research: BMS, Replimune, Novartis, Regeneron. Immunocore, Iovance

    Scott

    McGee-Plys

    NA

    Jill

    Wall

    NA

    Mary Susan

    Warsey

    NA

     

    Method of Participation and Request for Credit
    During the period 9/15/21 through 9/15/24 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: November 02, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ANCC: 1 hour Contact Hour
  • ACPE: 1 hour Contact Hour
  • CAMPEP: 1 hour Medical Physics Continuing Education Credit

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 4: Managing Immune Checkpoint Inhibitor Adverse Events
    Collapse Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts

    Check out our updated version- Certificate in Cancer Immunotherapy - Module 2 (As of 11/14/2022*), Available now....

    • Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts
    • Release Date: October 26, 2020
    • Expiration Date: October 26, 2024
    • Date of Last Review: 10/12/2023
    • Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC)
    • Estimated time to complete the activity: 90 minutes
    • For additional information about the accreditation of this activity, please visit https://partnersed.com
    • Computer system hardware/software requirements: SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

     

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 2: Basic Cancer Immunotherapy Concepts, will cover the biological foundation of cancer immunotherapy, applying the basic immunology you learned in the last module to help lay the foundation for future topics in this program.


    Click on image for FREE PREVIEW


     




     

     

     

     

     

     

    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Educational Objectives                                                   

    Upon completion of this activity, participants should be able to:

    Basis of Tumor Immunosurveillance and Immunotherapy

    • Describe how the immune system recognizes and eliminates cancer cells, including the concept of immunologic memory.
    • Characterize the function of specific immune cell populations in mediating tumor immunotherapy and/or immune suppression.
    • Distinguish between immunosurveillance, immunoediting and immunotherapy of cancer.
    • Identify the implications of immune depleted, excluded and infiltrated tumor microenvironments.
    • Identify how both central and peripheral tolerance can impact immunosurveillance and immunotherapy.
    • Describe the difference between primary and acquired resistance to immunotherapy.
    • Apply concepts of the cancer-immunity cycle to identify how biomarkers inform and influence tumor immunotherapy.

     

    Immunologic effects of other therapies

    • Describe the immunologic effects of standard cancer therapeutics on the tumor microenvironment and immune system.
    • Describe the potential impact of other, non-cancer agents, on tumor immunotherapy responses and toxicities.
    • Characterize the impact of standard cancer treatments on the efficacy of cancer immunotherapy.
    • Characterize the impact of standard cancer treatments on the toxicity of cancer immunotherapy.
    • Distinguish total body versus focal radiotherapy effects.
    • Recognize the impact of intratumoral injection and other local therapies on the tumor microenvironment and anti-tumor immune response.

     


    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     

    Faculty and Disclosure of Conflicts of Interest
    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Presenting Faculty

    Conflict of Interest

    Hussein Tawbi, MD, PhD
    Deputy Chair and Professor, Department of Melanoma Medical Oncology
    Director of Melanoma Clinical Research & Early Drug Development
    Co-Director, MD Anderson Brain Metastasis Clinic
    University of Texas MD Anderson Cancer Center, Houston, TX

    • Consultant: Genentech, BMS, Novartis, Merck, Array
    • Contracted Research: Genentech, BMS, Novartis, Merck, GSK

     

     

    Certificate Program Task Force

    Conflict of Interest

    Robert L. Ferris, MD, PhD (Chair)
    UPMC Hillman Cancer Center

    • Researcher: Astra-Zeneca/Medimmune, Bristol Myers Squibb, Merck, Novasenta, Tesaro
    • Consultant/Advisor/Speaker: Achilles Therapeutics; Adagene Incorporated, Adaptimmune, Aduro Biotech Inc, Astra-Zeneca/MedImmune; Bicara Therapeutics, Inc, Bristol-Myers Squibb, Brooklyn Immunotherapeutic, Cantenion, Coherus BioSciences, Inc, CureVac, Cytoagents, Eisai Europe Limited, EMD Serono, Everest Clinical Research Corporation, F. Hoffman-La Roche Ltd., Federation Bio, Inc, Genmab, Genocea Biosciences, Inc, Hookipa Biotech GmbH, Instill Bio, Inc, Kowa Research Institute, Inc, Lifescience Dynamics Limited, MacroGenics, Inc, MeiraGTx, LLC, Merck, Merus N.V, Mirati Therapeutics, Inc, Mirror Biologics Inc, Nanobiotix, Novartis Pharmaceutical Corporation, Novasenta, Numab Therapeutics AG, OncoCyte Corporation, Pfizer, PPD Development, L.P., Rakuten Medical, Inc, Regeneron, Sanofi, Seagen, Inc, SIRPant Immunotherapeutics, Inc, Tesaro, Vir Biotechnology, Inc, Zymeworks Inc
    • Stock holder: Novasenta

    Umar Farooq, MD
    University of Iowa

    • Researcher: Regeneron Pharmaceuticals
    • Consultant/Advisor/Speaker: Immpact Bio, Caribou Biosciences, Kite Pharma, MoprhoSys

    Silvia Formenti, MD
    Weill Cornell Medicine

    • Grant/Research Support: Bristol Myers Squibb, Varian, Regeneron, Merck, Celldex, ViewRay, AstraZeneca
    • Consultant/Honoraria: Bayer, Bristol Myers Squibb, Varian, ViewRay, Elekta, Janssen, Regeneron, GlaxoSmithKline, Eisai, Astra Zeneca, MedImmune, Merck US, EMD Serono/Merck, Genentech/ROCHE, Nanobiotix

    Sigrun Hallmeyer, MD
    Advocate Medical Group

    • Consultant: Cardinal Health

    Jose Lutzky, MD, FACP
    University of Miami Sylvester Cancer Center

    • Researcher: BMS
    • Consultant/Advisor/Speaker: Castle, Iovance, Vyriad, Replimune, Takeda, Oncotelic, T-Nanobio, Agenus, Celldex
    • Independent Contractor: BMS, Novartis, Iovance, Replimune, Regeneron, InstilBio, Syntrix, BioNtech, Foghorn, Trisalus, Agenus, Inmatics, Takeda, Dragonfly

    George Weiner, MD
    University of Iowa

    • Researcher: Regeneron, Pfizer

     

     

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.


     

    Instruction for Credit

    During the period 10/27/2023 through 10/27/24 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.
    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

     

    Joint Accreditation Statement
    Physicians / Nurses / Pharmacists

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Education
    PACE designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    American Board of Internal Medicine (ABIM) Maintenance of Certification
    A close up of a signDescription automatically generated Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development
    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

     

    Pharmacy Continuing Education
    PACE designates this continuing education activity for 1.5 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
    (Universal Activity Number - JA4008073-9999-23-272-H01-P)
    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Medical Physicist (CAMPEP)
    This program has been approved by The Commission on Accreditation of Medical Physics Education Programs (CAMPEP) for 1.50 MPCEC Hours. 2162188.

    You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.

     

    Media
    Internet

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: October 26, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 0.00 hours Certificate of Participation
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1.50 hours Contact Hour
  • ANCC: 1.50 hours Contact Hour
  • CAMPEP: 1.50 hours Medical Physics Continuing Education Credit

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 2: Basic Cancer Immunotherapy Concepts
    Collapse Certificate in Cancer Immunotherapy Module 1: Basic Immunology Concepts

    Published August 3, 2020

    Check out our updated version- Certificate in Cancer Immunotherapy - Module 1 (As of 10/14/2022*), Available now....

     

    Course Description
    This interactive online course is part of the Certificate in Cancer Immunotherapy program, produced by the Society for Immunotherapy of Cancer (SITC). The purpose of the certificate program is to provide hospitals, medical centers, third-party payers, referring physicians, trainees and patients with an identifiable designation for healthcare providers who can safely and effectively participate in administration of immunotherapies and manage patients treated with these approaches. View all eight modules of the program and a detailed description of the program here.

    This course, Module 1: Basic Immunology Concepts, will cover some of the key immunology needed to understand the rest of the certificate program.


    Click on image for FREE PREVIEW



    Target Audience
    The program is available to licensed physicians (U.S. licensed MD / DO or global equivalent). The courses and earning of the certificate (SITC-G; G = graduate) are also available to practicing, licensed NPs, PAs, and PharmDs or global equivalent. RPh degree holders are eligible if they are involved in direct clinical services. The courses are available to others who are not practicing clinicians, but they will not be eligible to earn the certificate.

    Faculty
    Robert L. Ferris, MD, PhD
    Hillman Professor of Oncology
    Director, UPMC Hillman Cancer Center
    Associate Vice Chancellor for Cancer Research
    University of Pittsburgh Medical Center, Pittsburgh, PA

     

    Learning Objectives

    Topic At the conclusion of this activity, the participant should be able to:

    Basic Properties of the Immune System

    • Describe the differences between innate immunity and adaptive immunity.
    • Describe the differences between humoral immunity and cellular immunity.
    • Describe the concept of self/non-self discrimination and immunologic memory.

    Cells and Tissues of the Immune System

    • Distinguish between the basic cell types involved in the immune response and their function, including B cells, T cells, natural killer (NK) cells, monocytes/macrophages and dendritic cells (DC).
    • Describe the architecture and functions of various immunologic tissues including the thymus, spleen, lymph nodes and bone marrow.

    Innate Immunity

    • Describe the key components of innate immunity including pattern recognition receptors and cells of the innate immune system.
    • Describe the function and regulation of innate immunity.
    • Describe how activation of innate immunity influences adaptive immune response.
    • Recognize how host cell death influences innate immunity. 

    Adaptive Immunity

    • Describe the components of the adaptive immune system including both humoral and cellular immunity.
    • Describe the function and regulation of adaptive immunity.
    • Define immune tolerance.
    • Describe how immune tolerance impacts adaptive immunity.

    Antigen Presentation

    • Distinguish class I and class II MHC antigen presentation.
    • Describe antigen uptake, processing and presentation.
    • Describe the concept of cross-presentation.

    Effector Immune Responses

    • Identify the cell populations involved in effector immune responses.
    • Describe the different mechanisms of effector functions.
    • Describe how effector functions are regulated.

    Inhibitory and Activating Immune Regulation

    • Describe the functions of major suppressive cell populations (regulatory T cells [Treg], and myeloid derived suppressor cells [MDSC])
    • Describe immunological synapses.
    • Describe the molecular mechanisms of immune cell activation.
    • Describe the molecular mechanisms of immune cell inhibition.
    • Distinguish between immune cell activation and inhibition of suppression as a pharmacological strategy.

    Integration of the Immune Response

    • Describe how the arms of the immune system interact.
    • List the host factors that influence the immune response.
    • List the environmental factors that influence the immune response.

     


     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     



    Continuing Education Information

    Date of CE Release:  August 3, 2020
    Date of CE Expiration: August 3, 2025
    Approximate Time to Complete:  90 minutes

    Acknowledgement of Financial Commercial Support
    No financial commercial support was received for this educational activity.

    Acknowledgement of In-Kind Commercial Support
    No in-kind commercial support was received for this educational activity.

    Satisfactory Completion

    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts to correctly answer 24 out of 30 questions) and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Society for Immunotherapy of Cancer.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Amedco Joint Accreditation # 4008163.

     

    Physicians (ACCME) Credit Designation

    Amedco LLC designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

     

    Nurses (ANCC) Credit Designation

    Amedco LLC designates this activity for a maximum of 1.50 ANCC contact hours.

     

    Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

    Amedco LLC designates this activity for a maximum of 1.50 knowledge-based CPE contact hours.

    UAN(s): JA4008163-9999-23-161-H99-P / JA4008163-9999-23-161-H99-T

     

    NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor. 

     

    Medical Physicist (CAMPEP) Credit Designation

    This program has been approved by the Commission on Accreditation of Medical Physics Education Programs (CAMPEP) for a total of 1.50 MPCEC credit hours.

     

    American Board of Internal Medicine (ABIM) MOC Credit

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
     

    You must request your certificate within 30 days of the activity to meet the deadline for submission to PARS.


    Disclosure of Conflict of Interest

    The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­‐6.2, 6.5)

    All individuals in a position to control the content of CE are listed below.

     

    FIRST NAME

    LAST NAME

    RELATIONSHIP: COMMERCIAL INTEREST

    Umar Farooq Consultant: Kite Pharma, Inc

    Robert

    Ferris

    Consultant: Aduro Biotech, Inc, Amgen, Astra-Zeneca/MedImmune, Bain Capital Life Sciences, BMS, EMD Serono, GSK, Iovance Biotherapeutics, Inc, Lilly, MacroGenics, Inc, Merck, Nanobiotix, Numab Therapeutics AG, Oncorus, Inc, Ono Pharmaceutical Co. Ltd, Pfizer, PPD (Benitec, Immunicum), Regeneron Pharmaceuticals, Inc, Tesaro, Torque Therapeutics, TTMS, VentiRx Pharmaceuticals

    Contracted Research: Astra-Zeneca/MedImmune, BMS, Merck, Tesaro, TTMS

    Silvia Formenti Contracted Research: Bristol Myers Squibb, Varian, Eli-Lilly, Janssen, Regeneron,Eisai, Merck
    Sigrun Hallmeyer Consultant: Array, Bristol Myers Squibb (BMS), Cardinal Health; Speakers Bureau: BMS
    Sayali Hede NA
    Terri Holzen NA
    Howard Kaufman Employee: Immuneering Corporation
    Claire Leischer NA
    Jose Lutzky Consultant: Array, Castle, Kimera Labs
    Scott McGee-Plys NA
    Alicia Schuessler NA
    Jo Shultz NA
    Hussein Tawbi Consultant: Genentech, BMS, Novartis, Merck, Array; Contracted Research: Genentech, BMS, Novartis, Merck, GSK
    Lianne Wiggins NA

     

     

    Method of Participation and Request for Credit
    During the period 8/3/20 through 8/3/25 participants must read the learning objectives and faculty disclosures and study the educational activity.

    Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process. 

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content.

     

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Original Course Date: August 03, 2020
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1.50 hours AMA PRA Category 1 Credit(s)™
  • CoP: 1 hour Certificate of Participation
  • : 1.50 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1.50 hours Contact Hour
  • ANCC: 1.50 hours Contact Hour
  • CAMPEP: 1.50 hours Medical Physics Continuing Education Credit

  • MORE INFOMORE INFO Certificate in Cancer Immunotherapy Module 1: Basic Immunology Concepts
    2023 CE Courses
    Collapse 2023 Advances in Cancer Immunotherapy™: Patient education (Outpatient Cell therapies/T Cell Engagers)

    Published: On Date

     

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Additional support for this activity provided by:

     

    Course Description and Target Audience
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, advanced practitioners, emergency physicians and all members of the cancer team, the ACI program focuses on how to educate your patients about receiving inpatient/outpatient cellular therapies; including examples of practical implementation provided


    Estimated time to complete activity: 25 Minutes

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Understand the patient journey and how to prepare a patient for these steps.

    • To be informed of the many time points that require patient education and reinforcement.

    • Develop an understanding about the varying pieces of education necessary for patient success.

    • How to properly prepare patients and their caregivers for outpatient CAR-T cell therapy.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

    Faculty and Disclosure of Conflicts of Interest

    No relevant financial conflicts.

    Faculty
    Meaghan Ekstrom, BA, BSN, MSN, FNP-BC
    Massachusetts General Hospital
    Boston, MA

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Original Course Date: December 25, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Patient education (Outpatient Cell therapies/T Cell Engagers)
    Collapse 2023 Advances in Cancer Immunotherapy™: Difficult-to-treat Cases

    Published Date: 12/01/2023

    Expiration Date: 12/01/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. In the course Difficult-to-treat Cases, Subject Matter Expert- David A. Braun, MD, PhD of Yale School of Medicine has endorsed the effectiveness of Immunotherapy in treating patients with Renal Cell Carcinoma. There are 3 real life difficult to treat case scenarios that elaborate tests, treatment plans, and the outcomes. The Subject Matter Expert reinforced his treatment plans while sharing the risk factors involved using the results of various clinical trials.

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Identify the benefits and risks of adjuvant immune checkpoint inhibitor (ICI) therapy with help of case studies.
    • Recognize the differences between front-line ICI-based therapies for metastatic disease.
    • Explain the treatment options for “PD-1—refractory” disease.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    Faculty:

    David A. Braun, MD, PhD       

    Assistant Professor, Goodman and Gilman Yale Scholar- Yale Cancer Center, Yale School of Medicine

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Conflicts of Interest:
    Consultant/Advisor/Speaker: Exelixis, AVEO, Charles River Associates, Schlesinger Associates, Imprint Science, Insight Strategy, Trinity Group, Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post/Harborside, Targeted Oncology, AbbVie.

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-305-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 12/01/2023 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 75% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


     

    Original Course Date: December 01, 2023

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Difficult-to-treat Cases
    Collapse 2023 Advances in Cancer Immunotherapy™: irAEs associated with Cellular Therapies and T-cell Engagers

    Published: On 10/05/2023

     

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

     

    The course irAES associated with Cellular Therapies and T-cell Engagers starts with an overview of cellular therapies and bisepcific antibodies. Dr. Loretta Nastoupil of UT MD Anderson Cancer Center has described the immune related acute and late adverse events associated with CAR T-cell therapies and potential approches to management of toxicities. The case studies presented by Dr. Nastoupil help decide the best possible action plan for managing toxicities associated with CAR T-cell therapies in patients.


    Estimated time to complete activity:  40 Minutes

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Give a brief overview of the mechanism of action and common toxicities associated with cellular therapies and T cell engagers.

    • List the multiple approaches that should be followed post treatment.

    • Describe the immune related acute and late adverse events (toxicities) associated with CAR-T cell therapies.

    • Describe similar acute toxicities associated with T-cell engagers and potential different approaches to management.

    • Explain the action plan for the management of toxicities associated with CAR-T cell therapies.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

    Faculty and Disclosure of Conflicts of Interest

     

    Faculty
    Loretta Nastoupil, MD
    Associate Professor
    UT MD Anderson Cancer Center
    Texas, USA

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Conflicts of Interest
    Researcher: BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, Takeda
    Consultant/ Advisor/ Speaker: Abbvie, Atara, BMS, Caribou Biosciences, Daiichi Sankyo, Epizyme, Genentech, Gilead/Kite, Janssen, Merck, Novartis, Takeda


    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Original Course Date: October 06, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: irAEs associated with Cellular Therapies and T-cell Engagers
    Collapse 2023 Advances in Cancer Immunotherapy™: Combination Therapies in Combating Cancer

    Published: On 08/11/2023

     

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

     

    The course- Combination therapies in Combating Cancer gives a brief overview of the several combination therapies such as Inhibitory Immune Checkpoint Combination therapy, Targeted Immunotherapy approches, and other emerging combination therapies. In this course, the subject matter expert describes the effectiveness of various combination immunotherpy approches and their outcomes in cancer patients using several case studies and research papers. The course content emphasizes the emerging landscape of combining immunotherapy with different modalities to treat cancer. 

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete activity:  1 hour

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Describe key immunotherapy targets that are useful for combination approaches.
    • Describe immunotherapy-based combination treatment regimens currently under investigation.
    • Discuss the emerging landscape of combining immunotherapy with different modalities to treat cancer.

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

    Faculty
    Gregory B. Lesinski, PhD, MPH
    Co-Director, Translational GI Malignancy Program
    Winship Cancer Institute of Emory University,
    Atlanta, Georgia, USA

     

    Disclosure of Conflicts of Interest
    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
    Gregory B. Lesinski, PhD, MPH: Works at a Academic Medical Center and a consultant advisor speaker for Bristol-Myers Squib, Vaccinex, Boerhinger-Ingelheim, Merck and Co.

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     

    Original Course Date: August 11, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Combination Therapies in Combating Cancer
    Collapse 2023 Advances in Cancer Immunotherapy™: Introduction to Biomarkers

    Published Date: 06/30/2023

    Expiration Date: 06/30/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Introduction to Biomarkers provides an overview on types of biomarkers and its significance in treatment of cancer. The SME has discussed various findings and outcomes of the clinical trial initiatives related to biomarkers.

     

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Define the term biomarker.
    • Explain the functions of biomarkers.
    • Differentiate the biomarkers based on their types.
    • Describe the use of biomarkers in various cancer treatments.
    • Summarize the challenges of using biomarkers in the treatment of cancer.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

     

    Faculty:

    Dr. Paolo A. Ascierto, MD
    Director of Department of Melanoma
    UOC Melanoma, Immunoterapia Oncologica e Terapie Innovative
    Istituto Nazionale Tumori – Fondazione “G. Pascale”
    Napoli, Italy

     

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

     

    Conflicts of Interest:
    Researcher: Bristol Myers Squibb, Roche-Genentech, Pfizer, Sanofi
    Consultant/Advisor/Speaker: Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna, Bio-Al Health, ValoTX, Replimmune, Bayer

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-162-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 06/30/2023 through 06/30/2024, participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


     

    Original Course Date: June 30, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Introduction to Biomarkers
    Collapse 2023 Advances in Cancer Immunotherapy™: Mechanisms of Immune-related Adverse Events (irAEs)

    Published Date: 06/01/2023

    Expiration Date: 06/01/2024

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. The course, Mechanisms of Immune-related Adverse Events (irAEs) provides an insight into the host factors that increase the risk of irAEs. The course briefly explains the differences in toxicities of CTLA-4 and PD-1 immune checkpoint inhibitors. The two case studies presented in course enables the learners to assess the immune-related response of immunotherapy treatment in a patient.

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 45 minutes

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC ConnectEd requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Explain the Mechanisms of immune related Adverse Events in brief.
    • Describe the other host factors that affect the risk of immune related Adverse Events.
    • Summarize the differences in PD-L1 and CTLA-4 toxicities.
    • Explain the response assessment process in a patient for the immunotherapy treatment.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    Faculty:

    Pradnya Patil, MD, FACP
    Associate Staff Oncologist
    Taussig Cancer Center, Cleveland Clinic
    Cleveland, OH

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Conflicts of Interest:
    Consultant/Advisor/Speaker: AstraZeneca, Jazz Pharmaceuticals

     

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.75 contact hours.

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-151-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 06/01/2023 through 06/01/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Original Course Date: May 30, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)™
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.75 hours Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Mechanisms of Immune-related Adverse Events (irAEs)
    Collapse 2023 Advances in Cancer Immunotherapy™: Introduction to Immunology

    Published Date: 05/05/2023

    Expiration Date: 05/05/2024

     

     

    Jointly provided by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).

    The 2023 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team. The ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

    This course, Introduction to Immunology provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy.

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete the activity: 1 hour

    For additional information about the accreditation of this activity, please visit https://partnersed.com

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 
     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, and other healthcare providers who care for patients with cancer.

                                                                                                                               

    Educational Objectives:                                                  

    Upon completion of this activity, participants should be able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules, and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanism by which tumors locally disable and/or evade the immune system.

     

    Faculty and Disclosure of Conflicts of Interest

    PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

    Faculty:

    Chrystal M. Paulos, PhD
    Director of Translational Research, Cutaneous Malignancies
    Winship Cancer Institute at Emory University

    The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

    Conflicts of Interest:
    IP Rights: Ares Immunotherapy
    Consulting Fees: Ares Immunotherapy
    Founder/Owner: Ares Immunotherapy
    Other (subcontracts): Obsidian, Lycera, ThermaFisher

     

    The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The SITC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Society for Immunotherapy of Cancer (SITC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Education

    PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    American Board of Internal Medicine Maintenance of Certification

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

     

    Nursing Continuing Professional Development

    The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours. Designated for 0.5 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses. 

     

    Pharmacy Continuing Education

    PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008073-9999-23-142-H01-P)

    Type of Activity: Knowledge

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Instructions for Credit

    During the period 05/05/2023 through 05/05/2024 participants must read the learning objectives and faculty disclosures and study the educational activity. Once the participant has passed the post-test with a score of 80% or higher (unlimited attempts allowed), and the course evaluation has been completed, credit will be automatically requested to the CRO the participant has selected during the registration process.

    Certificates will be available to the participant for printing after passing the post-test and completing the course evaluation.

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

     

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Original Course Date: May 05, 2023
    On-Demand Release Date: Available Now

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)™
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Introduction to Immunology
    Collapse 2023 Advances in Cancer Immunotherapy™: Basic Principles of Cancer Immunotherapy

    Published: On 04/28/2023

    Please note, this activity does not offer continuing education credit.

    The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

    Additional support for this activity provided by:

     

    Course Description
    This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future.

    This course, Basic Principles of Cancer Immunotherapy will walk the learner through the biological foundations of immunotherapy, types of immunotherapies, illustrate how biomarkers play a major role in immunotherapy, as well as cover the patient response to immunotherapy and subsequent physician assessment.  

    View all available ACI online offerings at www.sitcancer.org/acionline.

     

    Estimated time to complete activity:  1 hour

     

    Target Audience
    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Learning Objectives
    At the conclusion of this activity, the participant should be able to:

    • Describe the concept of Immunotherapy.
    • Identify the various types of cancer immunotherapy.
    • Describe the rationale for common approaches to cancer immunotherapy.
    • Explain the response assessment process in a patient for the immunotherapy treatment.

     

     

    Satisfactory Completion
    Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, pass the post-test with a score of 80% or higher (unlimited attempts) and complete an evaluation form/Survey to receive a certificate of completion.

     

     

    Faculty
    Christian M. Capitini, MD
    Associate Professor
    University of Wisconsin-Madison

    Disclosure of Conflicts of Interest
    The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 
    Christian M. Capitini, MD: Works at a Academic Medical Center and a consultant advisor speaker for Bayer, Elephas, Novartis, Nektar Therapeutics, WiCell Research Institute

    The Society for Immunotherapy of Cancer planners and others have nothing to disclose.

     

    SITC Online Education Disclaimer
    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all the information and data before treating patients or employing any therapies described in this educational activity. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

     

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

     

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


     

     

    Original Course Date: April 28, 2023

    Approved Credit:
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2023 Advances in Cancer Immunotherapy™: Basic Principles of Cancer Immunotherapy
    2022 CE Courses
    2021 CE Courses
    2020 CE Courses